Commonwealth Equity Services LLC Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Commonwealth Equity Services LLC raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 21.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,158 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,318 shares during the period. Commonwealth Equity Services LLC’s holdings in Jazz Pharmaceuticals were worth $1,585,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after purchasing an additional 29,960 shares in the last quarter. Polaris Capital Management LLC raised its position in Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after purchasing an additional 165,200 shares in the last quarter. Pacer Advisors Inc. raised its position in Jazz Pharmaceuticals by 28.1% during the fourth quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares in the last quarter. Baupost Group LLC MA raised its position in Jazz Pharmaceuticals by 23.7% during the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $89,175,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Needham & Company LLC reduced their price objective on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a research note on Thursday, June 20th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, March 22nd. Stifel Nicolaus raised their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, StockNews.com cut Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $188.62.

Read Our Latest Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $101.27 on Friday. The stock’s 50 day simple moving average is $108.46 and its two-hundred day simple moving average is $116.12. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.59 and a beta of 0.58. Jazz Pharmaceuticals plc has a fifty-two week low of $100.34 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, analysts expect that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Read More

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.